Trial Profile
A prospective study of Infliximab on Economic impacts, health outcomes and cost effectiveness in Chinese subjects with Rheumatoid Arthritis: A real world data.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Jun 2016
Price :
$35
*
At a glance
- Drugs Infliximab (Primary) ; Disease-modifying antirheumatics
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- 03 Jun 2016 New trial record
- 25 May 2016 Results presented at the 21st Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research